| |
OneKey provides email and state license data for DSCSA reporting, 100% coverage of federally reportable HCPs and HCOs for open payment, helps identify eligible practitioners for samples, and aids license verification and addresses. 
|
|
| By Gabrielle Masson A young boy with Duchenne muscular dystrophy participating in Pfizer’s phase 2 gene therapy trial has died, the pharma shared in a May 7 letter cited by nonprofit Parent Project Muscular Dystrophy. |
|
|
|
By Max Bayer Sanofi CSO Frank Nestle is leaving the company, a spokesperson confirmed. He joined the French pharma in 2016. |
By Eric Sagonowsky,Fraiser Kansteiner Kenvue’s board of directors on Monday approved a plan to cut 4% of the company’s global workforce. The J&J spinoff employed about 23,000 staffers at the end of last year, so the layoff initiative could affect some 920 workers. |
By Angus Liu Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities. |
By Helen Floersh A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism appears to prolong survival both in dogs and in humans, the results of a small study suggest. |
By Conor Hale The watch’s sensor and software marked the first digital health product to be qualified under the agency’s Medical Device Development Tools program. |
By Angus Liu ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the BCG vaccine to treat certain bladder cancers. Problem is, there is an ongoing global shortage of BCG, and ImmunityBio’s competitor, Merck & Co., is the sole supplier of BCG in the U.S. |
By Annalee Armstrong After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D. |
By Gabrielle Masson The Novo Nordisk Foundation, Wellcome and the Bill & Melinda Gates Foundation have inked a $300 million R&D initiative focused in part on infectious diseases and antimicrobial resistance. |
By Andrea Park In an ongoing battle for dominance in the eyes of healthcare professionals for their work developing heart-disease-focused drugs, Novartis has now snatched the top spot from Pfizer, according to a recent report from ZoomRx. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” Fierce Healthcare Senior Writer Anastassia Gliadkovskaya sits down with two experts to discuss how stakeholders can help overcome the issues plaguing the veteran healthcare system. |
|
|---|
|
|
Whitepaper In this free white paper, discover how consumer health and pharma leaders are harnessing the power of virtual care platforms and clinical networks to break down barriers to care, enhance accessibility, and revolutionize the patient / consumer experience - ultimately redefining the landscape of healthcare delivery. Sponsored by: Wheel |
Whitepaper How one top pharma increased literature reviews efficiency by 3x powered by AI -- download today Sponsored by: IQVIA |
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Presented by: Lonza |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain. Download this eBook to learn more about the future state of health care dynamics and its affects along the pharmaceutical value chain. Presented by Optum Life Sciences and Advisory Board |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
